Protocol for a randomized clinical trial exploring the effect of antimicrobial agents on the penile microbiota, immunology and HIV susceptibility of Ugandan men

Ronald M Galiwango, Bernard Bagaya, Juliet Mpendo, Vineet Joag, Brenda Okech, Annet Nanvubya, Ali Ssetaala, Moses Muwanga, Rupert Kaul, Ronald M Galiwango, Bernard Bagaya, Juliet Mpendo, Vineet Joag, Brenda Okech, Annet Nanvubya, Ali Ssetaala, Moses Muwanga, Rupert Kaul

Abstract

Background: The foreskin is the main site of HIV acquisition in a heterosexual uncircumcised man, but many men in endemic countries are reluctant to undergo penile circumcision (PC). Observational studies suggest that proinflammatory anaerobic bacteria are enriched on the uncircumcised penis, where they may enhance HIV susceptibility through increased foreskin inflammatory cytokines and the recruitment of HIV-susceptible CD4+ target cells. This trial will examine the impact of systemic and topical antimicrobials on ex vivo foreskin HIV susceptibility.

Methods/design: This randomized, open-label clinical trial will randomize 125 HIV-negative Ugandan men requesting voluntary PC to one of five arms (n = 25 each). The control group will receive immediate PC, while the four intervention groups will defer PC for 1 month and be provided in the interim with either oral tinidazole, penile topical metronidazole, topical clindamycin, or topical hydrogen peroxide. The impact of these interventions on HIV entry into foreskin-derived CD4+ T cells will be quantified ex vivo at the time of PC using a clade A, R5 tropic HIV pseudovirus assay (primary endpoint); secondary endpoints include the impact of antimicrobials on immune parameters and the microbiota of the participant's penis and of the vagina of their female partner (if applicable), assessed by multiplex enzyme-linked immunosorbent assay and 16S rRNA sequencing.

Discussion: There is a critical need to develop acceptable, simple, and effective means of HIV prevention in men unwilling to undergo PC. This trial will provide insight into the causative role of the foreskin microbiota on HIV susceptibility, and the impact of simple microbiota-focused clinical interventions. This may pave the way for future clinical trials using low-cost, nonsurgical intervention(s) to reduce HIV risk in uncircumcised heterosexual men.

Trial registration: ClinicalTrials.gov, NCT03412071 . Retrospectively registered on 26 January 2018.

Keywords: Antimicrobials; Clinical trial; HIV transmission; Penile microbiome; Uganda.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Schedule of enrolment, interventions, and assessments. *Only applicable for control/nonintervention groups samples. NA = not applicable

References

    1. Baggaley R, Doherty M, Ball A, Ford N, Hirnschall G. The strategic use of antiretrovirals to prevent HIV infection: a converging agenda. Clin Infect Dis. 2015;60:S159–S160. doi: 10.1093/cid/civ091.
    1. Rodger AJ, Cambiano V, Bruun T, Vernazza P, Collins S, Degen O, Corbelli GM, Estrada V, Geretti AM, Beloukas A, et al. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. Lancet. 2019;393(10189):2428–38.
    1. UNAIDS . Global HIV & AIDS statistics — 2018 fact sheet. 2018.
    1. TenoRes Study G Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study. Lancet Infect Dis. 2016;16:565–575. doi: 10.1016/S1473-3099(15)00536-8.
    1. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med. 2005;2:e298. doi: 10.1371/journal.pmed.0020298.
    1. Bailey RC, Moses S, Parker CB, Agot K, Maclean I, Krieger JN, Williams CF, Campbell RT, Ndinya-Achola JO. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet. 2007;369:643–656. doi: 10.1016/S0140-6736(07)60312-2.
    1. Gray RH, Kigozi G, Serwadda D, Makumbi F, Watya S, Nalugoda F, Kiwanuka N, Moulton LH, Chaudhary MA, Chen MZ, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet. 2007;369:657–666. doi: 10.1016/S0140-6736(07)60313-4.
    1. Gray RH, Wawer MJ, Kigozi G. Programme science research on medical male circumcision scale-up in sub-Saharan Africa. Sex Transm Infect. 2013;89:345–349. doi: 10.1136/sextrans-2012-050595.
    1. Sgaier SK, Reed JB, Thomas A, Njeuhmeli E. Achieving the HIV prevention impact of voluntary medical male circumcision: lessons and challenges for managing programs. PLoS Med. 2014;11:e1001641. doi: 10.1371/journal.pmed.1001641.
    1. Kigozi G, Wawer M, Ssettuba A, Kagaayi J, Nalugoda F, Watya S, Mangen FW, Kiwanuka N, Bacon MC, Lutalo T, et al. Foreskin surface area and HIV acquisition in Rakai, Uganda (size matters) AIDS. 2009;23:2209–2213. doi: 10.1097/QAD.0b013e328330eda8.
    1. Prodger JL, Gray R, Kigozi G, Nalugoda F, Galiwango R, Hirbod T, Wawer M, Hofer SO, Sewankambo N, Serwadda D, Kaul R. Foreskin T-cell subsets differ substantially from blood with respect to HIV co-receptor expression, inflammatory profile, and memory status. Mucosal Immunol. 2012;5:121–128. doi: 10.1038/mi.2011.56.
    1. Prodger JL, Hirbod T, Kigozi G, Nalugoda F, Reynolds SJ, Galiwango R, Shahabi K, Serwadda D, Wawer MJ, Gray RH, et al. Immune correlates of HIV exposure without infection in foreskins of men from Rakai, Uganda. Mucosal Immunol. 2014;7:634–644. doi: 10.1038/mi.2013.83.
    1. Prodger JL, Gray RH, Shannon B, Shahabi K, Kong X, Grabowski K, Kigozi G, Nalugoda F, Serwadda D, Wawer MJ, et al. Chemokine levels in the penile coronal sulcus correlate with HIV-1 acquisition and are reduced by male circumcision in Rakai, Uganda. PLoS Pathog. 2016;12:e1006025. doi: 10.1371/journal.ppat.1006025.
    1. Liu CM, Prodger JL, Tobian AAR, Abraham AG, Kigozi G, Hungate BA, Aziz M, Nalugoda F, Sariya S, Serwadda D, et al. Penile anaerobic dysbiosis as a risk factor for HIV infection. MBio. 2017;8. 10.1128/mBio.00996-17.
    1. Esra RT, Olivier AJ, Passmore JA, Jaspan HB, Harryparsad R, Gray CM. Does HIV exploit the inflammatory milieu of the male genital tract for successful infection? Front Immunol. 2016;7:245. doi: 10.3389/fimmu.2016.00245.
    1. Liu CM, Hungate BA, Tobian AA, Ravel J, Prodger JL, Serwadda D, Kigozi G, Galiwango RM, Nalugoda F, Keim P, et al. Penile microbiota and female partner bacterial vaginosis in Rakai, Uganda. MBio. 2015;6:e00589.
    1. Armstrong NR, Wilson JD. Tinidazole in the treatment of bacterial vaginosis. Int J Women’s Health. 2010;1:59–65.
    1. Menard JP. Antibacterial treatment of bacterial vaginosis: current and emerging therapies. Int J Women’s Health. 2011;3:295–305. doi: 10.2147/IJWH.S23814.
    1. Jhingta P, Bhardwaj A, Sharma D, Kumar N, Bhardwaj VK, Vaid S. Effect of hydrogen peroxide mouthwash as an adjunct to chlorhexidine on stains and plaque. J Indian Soc Periodontol. 2013;17:449–453. doi: 10.4103/0972-124X.118315.
    1. Rashed HT. Evaluation of the effect of hydrogen peroxide as a mouthwash in comparison with chlorhexidine in chronic periodontitis patients: a clinical study. J Int Soc Prev Community Dent. 2016;6:206–212. doi: 10.4103/2231-0762.183114.
    1. Joag VR, McKinnon LR, Liu J, Kidane ST, Yudin MH, Nyanga B, Kimwaki S, Besel KE, Obila JO, Huibner S, et al. Identification of preferential CD4+ T-cell targets for HIV infection in the cervix. Mucosal Immunol. 2016;9:1–12. doi: 10.1038/mi.2015.28.
    1. Cavrois M, De Noronha C, Greene WC. A sensitive and specific enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes. Nat Biotechnol. 2002;20:1151–1154. doi: 10.1038/nbt745.
    1. Galiwango RMYS, Prodger JL, et al. HIV Research for prevention 2016: AIDS vaccine, microbicide and ARV-based prevention science. Chicago: AIDS Research and Human Retroviruses; 2016. HIV susceptibility in CD4+ T cells derived from the Inner versus outer foreskin.
    1. Joag V, Sivro A, Yende-Zuma N, Imam H, Samsunder N, Abdool Karim Q, Abdool Karim S, McKinnon L, Kaul R. Ex vivo HIV entry into blood CD4+ T cells does not predict heterosexual HIV acquisition in women. PLoS One. 2018;13:e0200359. doi: 10.1371/journal.pone.0200359.
    1. Fadrosh DW, Ma B, Gajer P, Sengamalay N, Ott S, Brotman RM, Ravel J. An improved dual-indexing approach for multiplexed 16S rRNA gene sequencing on the Illumina MiSeq platform. Microbiome. 2014;2:6. doi: 10.1186/2049-2618-2-6.
    1. Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, Fierer N, Pena AG, Goodrich JK, Gordon JI, et al. QIIME allows analysis of high-throughput community sequencing data. Nat Methods. 2010;7:335–336. doi: 10.1038/nmeth.f.303.
    1. Liu CM, Aziz M, Kachur S, Hsueh PR, Huang YT, Keim P, Price LB. BactQuant: an enhanced broad-coverage bacterial quantitative real-time PCR assay. BMC Microbiol. 2012;12:56. doi: 10.1186/1471-2180-12-56.
    1. Simpson EH. Measurement of diversity. Nature. 1949;163:688. doi: 10.1038/163688a0.
    1. Oksanen J, Blanchet FG, Kindt R, Legendre P, Minchin PR, O'Hara RB, Simpson GL, Solymos P, Stevens HH, Wagner H. Vegan: community ecology package. R Package Version 1. 2011. pp. 17–18.
    1. Kindt RC. A manual and software for common statistical methods for ecological and biodiversity studies. Nairobi: World Agroforestry Centre; (ICRAF); 2005. Tree diversity analysis.
    1. Goslee SC, Urban DL. The ecodist package for dissimilarity-based analysis of ecological data. J Stat Softw. 2007;7:1–19.
    1. Galiwango RM, Yegorov S, Joag V, Prodger J, Shahabi K, Huibner S, Muyanja E, Kabuubi BR, Namuniina A, Nalutaaya A, et al. Characterization of CD4(+) T cell subsets and HIV susceptibility in the inner and outer foreskin of Ugandan men. Am J Reprod Immunol. 2019;82(1):e13143. doi: 10.1111/aji.13143.
    1. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche PC, Krleza-Jeric K, Hrobjartsson A, Mann H, Dickersin K, Berlin JA, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158:200–207. doi: 10.7326/0003-4819-158-3-201302050-00583.
    1. Collaborators GH. Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2015: the Global Burden of Disease Study 2015. Lancet HIV. 2016;3:e361–e387. doi: 10.1016/S2352-3018(16)30087-X.
    1. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, Tappero JW, Bukusi EA, Cohen CR, Katabira E, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367:399–410. doi: 10.1056/NEJMoa1108524.
    1. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim JG, Kumwenda J, Grinsztejn B, Pilotto JH, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493–505. doi: 10.1056/NEJMoa1105243.
    1. Grinsztejn B, Hosseinipour MC, Ribaudo HJ, Swindells S, Eron J, Chen YQ, Wang L, Ou SS, Anderson M, McCauley M, et al. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infect Dis. 2014;14:281–290. doi: 10.1016/S1473-3099(13)70692-3.
    1. Gils T, Bossard C, Verdonck K, Owiti P, Casteels I, Mashako M, Van Cutsem G, Ellman T. Stockouts of HIV commodities in public health facilities in Kinshasa: barriers to end HIV. PLoS One. 2018;13:e0191294. doi: 10.1371/journal.pone.0191294.
    1. Harper KN. Does the shortage of antiretroviral drugs in Uganda signal a trend? AIDS. 2016;30:N19–N20.
    1. Mori AT, Owenya J. Stock-outs of antiretroviral drugs and coping strategies used to prevent changes in treatment regimens in Kinondoni District, Tanzania: a cross-sectional study. J Pharm Policy Pract. 2014;7:3. doi: 10.1186/2052-3211-7-3.
    1. Moriarty K, Genberg B, Norman B, Reece R. The effect of antiretroviral stock-outs on medication adherence among patients living with HIV in Ghana: a qualitative study. J Assoc Nurses AIDS Care. 2018;29:231–240. doi: 10.1016/j.jana.2017.09.014.
    1. Zakumumpa H, Dube N, Damian RS, Rutebemberwa E. Understanding the dynamic interactions driving the sustainability of ART scale-up implementation in Uganda. Glob Health Res Policy. 2018;3:23. doi: 10.1186/s41256-018-0079-6.
    1. Ayieko J, Brown L, Anthierens S, Van Rie A, Getahun M, Charlebois ED, Petersen ML, Clark TD, Kamya MR, Cohen CR, et al. “Hurdles on the path to 90-90-90 and beyond”: qualitative analysis of barriers to engagement in HIV care among individuals in rural East Africa in the context of test-and-treat. PLoS One. 2018;13:e0202990. doi: 10.1371/journal.pone.0202990.
    1. Kakaire T, Schlech W, Coutinho A, Brough R, Parkes-Ratanshi R. The future of financing for HIV services in Uganda and the wider sub-Saharan Africa region: should we ask patients to contribute to the cost of their care? BMC Public Health. 2016;16:896. doi: 10.1186/s12889-016-3573-0.
    1. Resch S, Ryckman T, Hecht R. Funding AIDS programmes in the era of shared responsibility: an analysis of domestic spending in 12 low-income and middle-income countries. Lancet Glob Health. 2015;3:e52–e61. doi: 10.1016/S2214-109X(14)70342-0.
    1. Schneider MT, Birger M, Haakenstad A, Singh L, Hamavid H, Chapin A, Murray CJ, Dieleman JL. Tracking development assistance for HIV/AIDS: the international response to a global epidemic. AIDS. 2016;30:1475–1479. doi: 10.1097/QAD.0000000000001081.
    1. Prodger JL, Kaul R. The biology of how circumcision reduces HIV susceptibility: broader implications for the prevention field. AIDS Res Ther. 2017;14:49. doi: 10.1186/s12981-017-0167-6.
    1. de Jong MA, de Witte L, Oudhoff MJ, Gringhuis SI, Gallay P, Geijtenbeek TB. TNF-alpha and TLR agonists increase susceptibility to HIV-1 transmission by human Langerhans cells ex vivo. J Clin Invest. 2008;118:3440–3452. doi: 10.1172/JCI34721.
    1. Nazli A, Chan O, Dobson-Belaire WN, Ouellet M, Tremblay MJ, Gray-Owen SD, Arsenault AL, Kaushic C. Exposure to HIV-1 directly impairs mucosal epithelial barrier integrity allowing microbial translocation. PLoS Pathog. 2010;6:e1000852. doi: 10.1371/journal.ppat.1000852.
    1. MacLaren DJ, McBride WJ, Kelly GC, Muller R, Tommbe R, Kaldor JM, Vallely AJ. HIV prevalence is strongly associated with geographical variations in male circumcision and foreskin cutting in Papua New Guinea: an ecological study. Sex Transm Infect. 2015;91:502–505. doi: 10.1136/sextrans-2014-051970.
    1. Vallely AJ, MacLaren D, David M, Toliman P, Kelly-Hanku A, Toto B, Tommbe R, Kombati Z, Kaima P, Browne K, et al. Dorsal longitudinal foreskin cut is associated with reduced risk of HIV, syphilis and genital herpes in men: a cross-sectional study in Papua New Guinea. J Int AIDS Soc. 2017;20:21358. doi: 10.7448/IAS.20.01/21358.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe